REAC Cervicobrachial Neuromodulation Treatment of Depression, Anxiety, and Stress During the COVID-19 Pandemic

Figures & data

Table 1 DASS-21 Test Assessment Score

	Depression	Anxiety	Stress
Normal	0–9	0–7	0–14
Mild	10–13	8–9	15–18
Moderate	14–20	10–14	19–25
Severe	21–27	15–19	26–33
Extremely severe	28+	20+	34+

Figure 1 The image shows the administration of the NPPO-CB treatment. (A) Device based on REAC technology, model BENE 110 (ASMED, Florence, Italy); (B) Asymmetric conveyer probe (ACP). The ACP is connected to device (A) via a specific connection cable (C). The ACP is held in place using an elastic tubular mesh (D).

Figure 2 Graph of distribution of participants by severity level before and after REAC NPO, and NPPO-CB treatments for the depression cluster.

Figure 3 Graph of distribution of participants by severity level before and after REAC NPO, and NPPO-CB treatments for the anxiety cluster.

Figure 4 Graph of distribution of participants by severity level before and after REAC NPO, and NPPO-CB treatments for the stress cluster.

Figure 5 Group of the participants positive to DASS-21 test. The graph shows the improved values, moving towards the lower threshold of the normal range in all three clusters, before and after REAC NPO, and NPPO-CB treatments.

Figure 6 Group of the participants negative to all three clusters of DASS-21 test. The graph shows the improved values, moving towards the lower threshold of the normal range in all three clusters, before and after REAC NPO, and NPPO-CB treatments.

Table 2 Statistical Analysis – Sign Test and Wilcoxon Test

Sign Test	Depression	Anxiety	Stress
	Post Treatment – Pre Treatment	Post Treatment – Pre Treatment	Post Treatment – Pre Treatment
Z	−10.369	−9.518	−10.604
Asymp. p (2-tailed)	<0.001	<0.001	<0.001
Wilcoxon Test	Post treatment – pre treatment	Post treatment – pre treatment	Post treatment – pre treatment
Z	−9.663^a	−9.268^a	−10.230^a
Asymp. p (2-tailed)	<0.001	<0.001	<0.001

Note: ^aBased on positive ranks.